Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly announces successful Zyprexa settlement

Eli Lilly announces successful Zyprexa settlement

26th March 2008

Eli Lilly has announced the successful resolution of its ongoing mediation regarding the use of Zyprexa (olanzapine), its treatment for schizophrenia and bipolar disorder.

This mediation had been ordered by trial Judge Mark Rinder ahead of the case between the firm and the State of Alaska earlier this month, with efforts renewed last week by presiding Judge Morgan Christen.

The State of Alaska had filed a lawsuit relating to the use of the compound by the state’s Medicaid programme.

Under the terms of the settlement, Eli Lilly will pay $15 million (7.6 million pounds), as well as resolving that Alaska is treated as favourably as any other state that may settle with the firm over similar claims in the future.

Robert A Armitage, senior vice president and general counsel at Eli Lilly, said: “We believe this settlement is in the best interest of the company, the state, and, importantly, of the patients, families and healthcare professionals for whom Zyprexa is an important treatment option.”

The company added while it believes it had a “strong defence”, it concurs that an amicable resolution is the best result for all parties, avoiding the expenditure of time and resources of a two-phase trial.

Last month, Eli Lilly reported that Zyprexa has been shown to be an effective and safe treatment and maintenance therapy for adult schizophrenia patients.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.